Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.35 |
| ▸ | KDM1A | O60341 | 7/20 | 0.33 |
| ▸ | ITGAL | P20701 | 4/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE6C | P51160 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637433 | 1.00 | TRPV4 (0.35) | TRPV4KDM1AITGALITGB2ICAM1 | |
| SCHEMBL4637395 | 1.00 | TRPV4 (0.35) | TRPV4KDM1AITGALITGB2ICAM1 | |
| SCHEMBL4637346 | 0.85 | TRPV4 (0.34) | TRPV4ITGALITGB2ICAM1CNR1 | |
| SCHEMBL4638063 | 0.84 | TRPV4 (0.36) | TRPV4ITGALITGB2ICAM1CNR1 | |
| SCHEMBL4637464 | 0.84 | MCHR1 (0.36) | TRPV4KDM1AITGALITGB2ICAM1 | |
| SCHEMBL4637908 | 0.84 | TRPV4 (0.36) | TRPV4ITGALITGB2ICAM1CNR1 | |
| SCHEMBL4637461 | 0.84 | MCHR1 (0.36) | TRPV4KDM1AITGALITGB2ICAM1 | |
| SCHEMBL4639084 | 0.84 | MCHR1 (0.36) | TRPV4KDM1AITGALITGB2ICAM1 | |
| SCHEMBL4637903 | 0.84 | TRPV4 (0.36) | TRPV4ITGALITGB2ICAM1CNR1 | |
| SCHEMBL4799595 | 0.84 | CYP3A4 (0.37) | TRPV4CNR1PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262070-A1 | Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds | BAUMANN KARL | 2008-10-23 | — | — | US | disclosed |
| EP-1937685-A1 | TETRAHYDRO-PYRROLIZINONE COMPOUNDS AS LFA-I MEDIATORS | Novartis AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039286-A1 | TETRAHYDRO-PYRROLIZINONE COMPOUNDS AS LFA-I MEDIATORS | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262070-A1 | Pharmaceutically Active Tetrahydro-Pyrrolizinone Compounds | VCAM1, ICAM1, EPCAM | TRPV4 430/4885KDM1A 3314/4885ITGAL 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.